Aerie Pharmaceuticals, Inc. acquired by Alcon Research, Ltd.
Alcon Research, Ltd. acquired Aerie Pharmaceuticals, Inc., a US ophthalmic pharmaceuticals brand, on Nov 21, 2022.
Transaction summary
- Target
- Aerie Pharmaceuticals, Inc.
- Acquirer
- Alcon Research, Ltd.
- Announced
- 2022-08-22
- Geography
- United States
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- 100%
- First added
- 2026-08-08
- Latest update
- 2026-10-21
Value and multiples
100% enterprise value
USD 750M
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
4.4x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- MarketScreener reports that Alcon Research agreed to buy Aerie for about USD 750m on an enterprise-value basis; the USD 15.25 per-share cash price represents about USD 770m of equity value. The 4.4x revenue multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source. With USD 750m it implies revenue of about USD 170.5m; the period is not stated.
Source summary
Alcon Research, Ltd. completed the acquisition of Aerie Pharmaceuticals, Inc. from a group of shareholders.
EstimatedMarketScreener reports Alcon Research, Ltd. entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. for approximately $750 million, at $15.25 per share in cash, representing approximately $770 million equity value. The transaction was announced August 22, 2022 and completed November 21, 2022.
Open sourceContinue your research
Related transaction comps
Dersimelagon rights acquired by LEO Pharma
2026-08-18 · Confirmed
View transaction → PharmaEdgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction → PharmaTianjin TSKF Pharmaceutical Co., Ltd. acquired by Haleon plc
2025-06-27 · Confirmed
View transaction → ophthalmic pharmaceuticalsOyster Point Pharma acquired by Viatris
2022-11-07 · Confirmed
View transaction →